Results 291 to 300 of about 26,327 (353)

Authors' response: Oxygen therapy in heart failure. [PDF]

Eur Heart J Open
Tremblay-Gravel M, Boulet J, Tardif JC.
europepmc   +1 more source

Circulating CD19 B cell count, myocardial injury and clinical outcomes in patients with heart failure

ESC Heart Failure, Volume 12, Issue 5, Page 3512-3523, October 2025.
Circulating CD19 B cell counts negatively correlated with myocardial injury. CD19 B cell count was an independent predictor for all‐cause mortality and HF‐related events, but not other lymphocyte subsets. Circulating CD19 B cell counts correlated to myocardial injury and could be a feasible marker for clinical outcomes in patients with HF.
Yuta Kobayashi, Yoichiro Otaki, Tetsu Watanabe, Ryuhei Yamaguchi, Hiroe Ono, Shingo Tachibana, Junya Sato, Naoaki Hashimoto, Masahiro Wanezaki, Daisuke Kutsuzawa, Takanori Arimoto, Masafumi Watanabe   +11 more
wiley   +1 more source

Responses of B-type natriuretic peptide (BNP), mature BNP and proBNP to sacubitril/valsartan differs between responders and non-responders. [PDF]

Open Heart
Nishikimi T, Nakagawa Y, Miyamoto S, Kanamori T, Inazumi H, Yanagisawa H, Moriuchi K, Kinoshita H, Tamamura Y, Takahama H, Minamino N, Ono K.   +11 more
europepmc   +1 more source

Age‐adjusted natriuretic peptide thresholds for a diagnosis of heart failure in the community: Diagnostic accuracy study

ESC Heart Failure, Volume 12, Issue 5, Page 3552-3568, October 2025.
Abstract Background European Society of Cardiology (ESC) chronic heart failure (HF) guidelines recommend a single N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) threshold of ≥125 pg/mL for specialist referral in symptomatic patients; however, natriuretic peptide levels increase with age.
Clare J. Taylor, Kathryn S. Taylor, Nicholas R. Jones, Jose M. Ordóñez‐Mena, Antoni Bayes‐Genis, F.D. Richard Hobbs   +5 more
wiley   +1 more source

Implementation of Guideline-Directed medical therapy and factors in heart failure with reduced ejection fraction. [PDF]

BMC Cardiovasc Disord
Bekele FW, Alemu WA, Tolla KS, Jada AU, Tekle MA, Adem MK, Yesuf HA.   +6 more
europepmc   +1 more source

Initial clinical experience with dapagliflozin in addition to optimized medical therapy in paediatric heart failure patients

ESC Heart Failure, Volume 12, Issue 5, Page 3494-3501, October 2025.
Abstract Aims Dapagliflozin, a sodium‐glucose cotransporter 2 (SGLT2) inhibitor, has shown clinical benefits in adults with heart failure (HF), improving cardiac function, reducing HF‐related hospitalizations and enhancing survival rates. While extensively studied in adult HF, data on its efficacy and safety in paediatric HF patients remain limited. We
Lisa‐Maria Rosenthal, Oliver Miera, Annemarie Krauss, Friederike Danne, Felix Berger, Peter Kramer   +5 more
wiley   +1 more source

Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States. [PDF]

Front Cardiovasc Med
Greene SJ, Coyle CR, Hancock LN, Tebbs KW, Barlow SG, Stevenson AS, Obi EN.   +6 more
europepmc   +1 more source

Relationship of malnutrition and frailty on prolonged stay at the hospital in heart failure patients

ESC Heart Failure, Volume 12, Issue 5, Page 3614-3623, October 2025.
This abstract presents a study of 200 heart failure patients (average age 72.3 years), assessing the relationship between malnutrition and frailty. Nutritional status was evaluated using the Mini Nutritional Assessment: 63.5% had normal nutrition, 35% were at risk, and 1.5% were malnourished.
Katarzyna Lomper, Maria Jędrzejczyk, Marta Wleklik, Izabella Uchmanowicz   +3 more
wiley   +1 more source

Comparison of Quadruple Therapy Sequencing Strategies for Heart Failure With Reduced Ejection Fraction. [PDF]

J Am Heart Assoc
Turgeon RD, Van MT, Loewen P, Sadatsafavi M, Zhang W, MacDonald BJ, MacKay K, Hawkins N.   +7 more
europepmc   +1 more source

Prognostic impact of peak oxygen consumption in heart failure: A systematic review and meta‐analysis

ESC Heart Failure, Volume 12, Issue 5, Page 3624-3642, October 2025.
Based on 64 studies, each 1 mL/kg/min increase in VO2peak significantly reduced all‐cause mortality (HR: 0.86, 95% CI 0.82–0.90) and combined outcomes of ventricular assist device, transplant and all‐cause mortality (HR: 0.84, 95% CI 0.79–0.89) in patients with heart failure, though no significant association was observed with cardiovascular mortality (
Konstantinos Prokopidis, Krzysztof Irlik, Julia Piaśnik, Zuzanna Michalska, Mirela Hendel, Katarzyna Nabrdalik, Gregory Y.H. Lip   +6 more
wiley   +1 more source